Bass suffers another IPR setback

Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office (USPTO) declined to institute an inter partes review (IPR) of a patent owned by Biogen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB deals Bass another blow

21 October 2015 The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

Americas

Bass set for first IPR trial as Shire petition proceeds

9 October 2015 Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.

Americas

Bass targets the University of Pennsylvania in IPR petitions

1 September 2015 Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Bass suffers another IPR setback

More on this story

Editor's picks

Editor's picks

More features